Receipt of deferred consideration

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Receipt of deferred consideration

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.

 

Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

Contacts:

 

Omega Diagnostics Group PLC	www.omegadiagnostics.com
Jag Grewal, Chief Executive	via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd	Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited	Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus / Sam Allen	Mob: 07980 541 893 / Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com